We aimed to perform a comprehensive molecular analysis of a large cohort of patients with RAD51C/D untreated primary breast cancer and ovarian cancer to describe the prevalence of HRD by different biomarkers and investigate the role of the germline alterations in tumorigenesis. This evidence concerns the gene RAD51C and breast cancer.